Over 15 days of combined CBD and THC in mice, CBD modestly inhibited THC's rebound hyperactivity and sensorimotor effects, but the combination produced unexpected epigenetic and molecular changes in the brain's reward pathway.
Readers using cannabis products that combine CBD and THC.
CBD+THC together caused unique epigenetic changes in reward circuits that neither compound caused alone
What the researchers found
Researchers examined whether CBD modulates THC's effects during repeated co-administration over 15 days in mice. The behavioral results were mixed: CBD modestly inhibited THC-induced rebound locomotor hyperactivity and slightly reduced acute sensorimotor gating effects, but only at a 1:1 ratio. Increasing to 5:1 CBD:THC did not enhance these effects. CBD did not alter THC-induced anxiety or the development of tolerance.
However, the molecular findings were more surprising. The combination of CBD and THC increased histone H3 acetylation (H3K9/14ac) in the ventral tegmental area (VTA) and ΔFosB expression in the nucleus accumbens, both markers associated with neuroadaptation in the reward pathway. These changes were not seen with either compound alone, suggesting their combination produces "supradditive" (greater than the sum of parts) molecular effects.
Importantly, there was no evidence of CBD potentiating THC's behavioral effects, but the long-term molecular changes suggest the brain's reward circuitry responds differently to the combination than to either compound individually.
Why it matters
Medical cannabis products like Sativex use specific CBD:THC ratios, and many consumers choose "balanced" products. This study suggests that while CBD may offer some acute behavioral protection against THC effects, the long-term molecular consequences of combining the two may be more complex than assumed. The epigenetic changes in reward circuitry warrant further investigation.
The numbers in context
15-day treatment period. CBD:THC ratios: 1:1 and 5:1. Modest behavioral effects at 1:1 only. Increased H3K9/14ac in VTA. Increased ΔFosB in nucleus accumbens. No CBD potentiation of THC behavior. No anxiety reduction from CBD co-administration.
How the study worked
Mice received 15 days of treatment with THC alone, CBD alone, or CBD+THC at 1:1 or 5:1 ratios. Behavioral tests included locomotor activity, sensorimotor gating, anxiety, and pharmacological tolerance. Brain tissue was analyzed for histone acetylation and ΔFosB expression in the mesolimbic dopamine pathway.
What this study cannot tell us
Mouse study that may not directly translate to humans. Only two CBD:THC ratios tested. The functional significance of the epigenetic changes (histone acetylation, ΔFosB) for behavior is not established by this study. The doses and treatment duration may not reflect typical human cannabis use patterns.
How to read the evidence
Preliminary evidence from a single animal study with novel epigenetic findings.
When this study was published
Published in 2017. Among the first studies to examine long-term molecular effects of CBD+THC combination.
The bigger picture
The "CBD protects against THC" narrative is popular but may be oversimplified. This study shows CBD's acute behavioral modulation of THC is subtle at best, and the long-term molecular picture is more complex, with the combination producing unique epigenetic changes in reward circuits that neither compound causes alone.
Questions still open
- Do the epigenetic changes from combined CBD+THC have functional consequences for reward sensitivity or addiction vulnerability? Would longer treatment periods amplify these molecular effects? Should medical cannabis dosing guidelines consider these unexpected molecular interactions?
Common questions
Does CBD cancel out THC's effects?
Is combining CBD and THC safer than THC alone?
Read the original research
Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 27(2), 132-145
Citation
Todd, Stephanie M; Zhou, Cilla; Clarke, David J; Chohan, Tariq W; Bahceci, Dilara; Arnold, Jonathon C. (2017). Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 27(2), 132-145. https://doi.org/10.1016/j.euroneuro.2016.12.004
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk